Genmab A/S (NASDAQ:GMAB) saw a large decline in short interest in September. As of September 15th, there was short interest totalling 656,300 shares, a decline of 32.4% from the August 31st total of 970,300 shares. Based on an average daily volume of 622,900 shares, the short-interest ratio is currently 1.1 days.
GMAB stock traded up $0.32 during trading on Thursday, hitting $36.93. The stock had a trading volume of 864,323 shares, compared to its average volume of 691,102. The company’s 50 day moving average price is $36.75 and its two-hundred day moving average price is $30.48. Genmab A/S has a 1-year low of $16.24 and a 1-year high of $38.87. The stock has a market cap of $23.95 billion, a price-to-earnings ratio of 15.13, a price-to-earnings-growth ratio of 1.27 and a beta of 0.80. The company has a debt-to-equity ratio of 0.02, a quick ratio of 9.53 and a current ratio of 9.53.
Genmab A/S (NASDAQ:GMAB) last announced its earnings results on Wednesday, August 12th. The company reported $0.76 earnings per share for the quarter, missing the consensus estimate of $0.88 by ($0.12). Genmab A/S had a net margin of 54.66% and a return on equity of 38.38%. The firm had revenue of $804.62 million during the quarter, compared to analyst estimates of $828.85 million. As a group, sell-side analysts forecast that Genmab A/S will post 1.05 earnings per share for the current fiscal year.
Several equities research analysts have commented on the stock. TheStreet upgraded shares of Genmab A/S from a “c” rating to a “b” rating in a research report on Friday, September 4th. JPMorgan Chase & Co. restated an “overweight” rating on shares of Genmab A/S in a research report on Friday, June 12th. BidaskClub lowered shares of Genmab A/S from a “buy” rating to a “hold” rating in a research report on Friday, September 25th. Bryan, Garnier & Co lowered shares of Genmab A/S from a “neutral” rating to a “sell” rating in a research report on Wednesday, September 23rd. Finally, Morgan Stanley boosted their target price on shares of Genmab A/S from $30.00 to $32.00 and gave the stock an “overweight” rating in a research report on Thursday, August 13th. Three equities research analysts have rated the stock with a sell rating, six have issued a hold rating and seven have given a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $37.14.
About Genmab A/S
Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL).
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.